Send to

Choose Destination
J Pediatr. 2008 Sep;153(3):350-3. doi: 10.1016/j.jpeds.2008.04.014. Epub 2008 Jun 2.

Influence of a patent ductus arteriosus on cardiac troponin T levels in preterm infants.

Author information

Department of Neonatology, National Maternity Hospital, Dublin, Ireland.



To evaluate the effect of patent ductus arteriosus (PDA) on the myocardium by measuring levels of cardiac troponin T (cTnT), a marker of ischemic myocardial damage.


Eighty infants with a median gestation of 28 weeks (interquartile range ([IQR] = 26.1 to 29.5 weeks) and median birth weight of 1.06 kg (IQR = 0.87 to 1.21 kg) underwent echocardiographic and cTnT assessments at 12 and 48 hours of life. The infants with PDA were treated with ibuprofen or surgical ligation. Follow-up echocardiography and cTnT assay was performed after treatment.


The median 12-hour cTnT level was 0.20 microg/L (IQR = 0.11 to 0.40 microg/L). At 48 hours, median cTnT level was significantly higher in the PDA group (n = 45) than in the spontaneous closure group (n = 35) (0.43 vs 0.13 microg/L; P < .001). Following successful treatment, cTnT levels decreased significantly, to 0.10 microg/L (P < .001). cTnT levels correlated significantly with ductal diameter, left atrial-to-aortic diameter ratio, and descending aortic end-diastolic velocity. The receiver operating characteristics curve for detection of PDA through cTnT values had an area under the curve of 0.78 (95% confidence interval = 0.66 to 0.90; P < .001).


cTnT may be a useful marker of ductal significance and treatment response, because it correlates with echocardiographic markers of PDA. Elevated cTnT level may reflect the potential myocardial damage caused by a PDA.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center